We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A California supplement maker is in hot water after being accused of making drug-like claims about its products and relying on improper production methods. Read More
Drugmarkers are reporting a 20 percent improvement in securing their supply chains compared with a year ago, according to findings from a new report. Read More
Two House members are asking two embattled drugmakers for information and documents related to some of their products ahead of a Jan. 26 hearing on prescription drug pricing. Read More
Botox maker Allergan shelled out $90 million upfront to acquire dermatology drugmaker Anterios in a deal that will provide access to a pipeline of neurotoxin therapies. Read More
Dr. Reddy’s Laboratories has adopted a unique strategy to bypass legal issues surrounding its generic version of Nexium: changing the color of its capsules. Read More
Participants in a Dec. 9, 2015, Senate hearing — which addressed drug price manipulation of generics in uncontested markets — said the best way to stem the practice is to speed competitors to market and consider using compounders. Read More